5:11 PM
 | 
Apr 16, 2013
 |  BC Extra  |  Company News

Sarepta falls after FDA data request

Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell $5.25 (13%) to $33.99 on Tuesday after FDA requested additional information from the company about the existing data set for eteplirsen to "inform a decision" on whether the data could support accelerated approval for Duchenne muscular dystrophy (DMD). Sarepta...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >